Brief: MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval
01/04/2025 14:36
April 1 (Reuters) - Maia Biotechnology Inc MAIA.A: MAIA BIOTECHNOLOGY- PHASE 2 TRIAL THIO-101 EXPANSION UNDERWAY; POTENTIAL FILING IN 2026 FOR ACCELERATED APPROVAL MAIA BIOTECHNOLOGY- PHASE 3 THIO-104 SET TO BEGIN IN MID-2025; POTENTIAL FILING IN 2026 FOR EARLY FULL APPROVAL Source text: ID:nBw3b4svwa Further company coverage: MAIA.A (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale